Delivers definitive biochemical evidence of traumatic brain injury (TBI) across any of stage of injury evolution and recovery: Acute (0–72 hours post-injury), Post-Acute (4 days to 6 weeks post-injury), and Chronic (6 weeks to more than 5 years post-injury). Provides mechanistically grounded insights into injury severity and the risk of long-term cognitive impairment. Objective, quantitative reporting supports early intervention, precision-guided treatment planning, and longitudinal tracking of recovery status.

This advanced blood-based assay quantifies concentrations of four clinically validated neurotrauma-related proteins – Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-terminal Hydrolase L1 (UCH-L1), S100ß, and Neurofilament-Heavy Chain (NF-H) – alongside two genetic markers known to influence post-TBI outcomes: Apolipoprotein E (APOE) and Methylenetetrahydrofolate Reductase (MTHFR). By integrating protein biomarker data with genetic risk factors, this multiplexed test captures both acute and chronic neurotrauma signatures while accounting for individual predisposition.

The current standard of care for traumatic brain injury (TBI) diagnostics is centered almost exclusively on the acute post-injury period, typically within the first 24 to 72 hours. Conventional clinical tools – which include symptom inventories, neurocognitive screens (e.g., MACE, MoCA), and structural imaging (CT, MRI) – are designed to detect gross abnormalities, intracranial bleeding, or acute functional impairments. However, these tools exhibit low sensitivity for mild-to-moderate TBI (mmTBI), and their diagnostic utility rapidly diminishes beyond the acute phase. As a result, the vast majority of TBI cases – especially those without overt radiographic findings – go undetected or misclassified, resulting in avoidable and often long-term neurological compromise.

Moreover, once the immediate injury window has passed, no clinically validated method exists to definitively confirm prior TBI, assess cumulative exposure, or determine recovery status. This not only impairs timely intervention but also precludes effective longitudinal care, contributing to persistent post-concussive symptoms (PCS), cognitive and functional decline, and elevated long-term disability rates.

The BioConnetiX TBI Pathway provides a managed care framework ensures those results are translated into standardized, protocol-driven care that reduces cost variability and prevents patients from slipping through gaps in the system.

BioConnetiX is a managed services and case management company that coordinates the diagnostic, clinical, and administrative components of advanced diagnostic pathways at the enterprise level.

Whether leveraging your care team or ours, we coordinate care teams, deliver training and decision-support tools, and offer one-touch access to subspecialist molecular pathologists via e-consult. Our enterprise solutions also enable longitudinal tracking and outcome analytics – transforming advanced diagnostics into a scalable, affordable care platform with measured outcomes. BioConnetiX offers end-to-end managed care solutions and a flexible pricing model, with both fee-for-service and risk-based options to meet the needs of your system.

• Objective Diagnosis – Delivers diagnostic accuracy, replacing subjective inputs with objective biomarkers to enable confident, evidence-based decisions
• Risk Stratification – Generates risk score (low, medium, high) for prolonged cognitive impairment, supporting targeted interventions that optimize recovery outcomes
• Longitudinal Monitoring – Enables serial tracking of neurological status to confirm injury resolution, detect ongoing neurodegeneration, and assess cumulative exposure